The CNCT19 CAR-T cell therapy is positioned to address a significant unmet need in the treatment of advanced hepatocellular carcinoma (HCC), particularly in patients who are not candidates for surgical intervention or have progressed after standard therapies. The market for HCC therapies is growing, driven by increasing incidence rates and the need for innovative treatments. Competitive landscape includes established CAR-T therapies and emerging candidates targeting HCC. Diligence should focus on the safety profile and efficacy outcomes of CNCT19, as well as potential partnerships or licensing opportunities with industry collaborators like Juventas Cell Therapy Ltd.